This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
Guidance for health care workers.
Both the REGN-EB3 and mAb114 are recommended for use in EVD. The two drugs should not be given together. The choice of which monoclonal antibody to use depends on availability, including emerging information about effectiveness.
Guidance for health care workers.
Both the REGN-EB3 and mAb114 are recommended for use in EVD. The two drugs should not be given together. The choice of which monoclonal antibody to use depends on availability, including emerging information about effectiveness.
Guidance for health care workers.
Both the REGN-EB3 and mAb114 are recommended for use in EVD. The two drugs should not be given together. The choice of which monoclonal antibody to use depends on availability, including emerging information about effectiveness.
Guidance for health care workers.
Both the REGN-EB3 and mAb114 are recommended for use in EVD. The two drugs should not be given together. The choice of which monoclonal antibody to use depends on availability, including emerging information about effectiveness.
Guidance for health care workers.
Guidance for health care workers.
This annual report highlights the work of the WHO from January to June 2021 ( December 2021). The activities featured herein are by no means exhausted but implemented with technical and financial support through WHO in Nigeria; facilitated by its presence at all levels of governance (national, state..., local government, and wards).
more
Juni 2021. Flyer zu Antigentests
In zahlreichen Sprachen herunterzuladen
21 July 2022. The Rapid Core CRF is designed to collect data obtained through examination, interview and review of
hospital or clinic notes of patients with suspected, probable, or confirmed monkeypox infection. Data
may be collected prospectively or retrospectively. The data collection period is ...defined as the period
from hospital admission or first clinic visit to discharge from care, transfer, death, or continued
hospitalization without possibility of continued data collection.
more
The Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations outline a public health response for 5 key populations (men who have sex with men, trans and gender diverse people, sex workers, people who inject drugs and people in prisons and... other closed settings). They present and discuss new recommendations and consolidate a range of recommendations and guidance from current WHO guidelines.
more
In this guideline, WHO recommends that long-acting injectable cabotegravir (CAB-LA) may be offered as an additional HIV prevention option for people at substantial risk of HIV infection. CAB-LA is an injectable form of pre-exposure prophylaxis (PrEP) that has been shown to be highly effective at red...ucing the risk of HIV acquisition.
This guideline provides implementation considerations to support Member States, programme managers, policy makers, researchers, health workers, communities, and other stakeholders in the implementation of projects and programmes for CAB-LA. It also outlines critical research gaps for CAB-LA.
more
Around the world, millions of refugees and migrants in vulnerable situations, such as low-skilled migrant workers, face poorer health outcomes than their host communities, especially where living and working conditions are sub-standard, according to the first WHO World report on the health of refuge...es and migrants. This has dire consequences for the probability that the world will not achieve the health-related Sustainable Development Goals for these populations.
more
Which communities are most at risk of Monkeypox in the current outbreak and why? WHO’s Andy Seale explains how we can support the communities at risk in Science in 5.
As a result of Russia’s invasion of Ukraine, the people of Ukraine, especially the most vulnerable, are paying an enormous price. Lives and livelihoods are being lost, with more than ten million people forced from their homes— and their country—in search of safety. The war has unleashed catast...rophic damage to the country’s economy and threatens lasting increases in poverty and societal upheaval. The scale of the war and the devastation it has caused have jeopardized Ukraine’s hard-fought development gains, through destruction of production and property, disruption of trade, diminished investment due to amplified uncertainty, and erosion of human capita
more